NCT05005845 2026-02-17
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
Phase 2 Completed
Clinical Trials
22 trialsNCT04481035 2025-07-31
NF1NAC
Children's Hospital Medical Center, Cincinnati
Phase 2 Completed
NCT00624234 2025-07-08
Neurobiology and Treatment of Reading Disability in NF-1
Vanderbilt University
Phase NA Completed
NCT05912400 2025-05-08
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
University of Arkansas
Completed
NCT03231306 2025-05-02
NF108-BINI
University of Alabama at Birmingham
Phase 2 Completed
NCT04561765 2025-03-30
Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
Yale University
Phase NA Completed
NCT01553149 2025-01-07
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03531814 2024-06-11
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
National Institutes of Health Clinical Center (CC)
Phase NA Completed
NCT02332902 2023-12-20
DCLNF1
The University of Texas Health Science Center, Houston
Phase 2 Completed
NCT02839720 2023-12-06
Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00846430 2023-08-30
Medical Treatment of "High-Risk" Neurofibromas
Corewell Health West
Phase 2 Completed
NCT04435665 2022-08-09
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
Phase 2 Completed
NCT02471339 2022-06-14
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT01125046 2021-01-22
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Northwestern University
Phase 2 Completed
NCT02096471 2019-01-10
MEK Inhibitor
University of Alabama at Birmingham
Phase 2 Completed
NCT00304083 2018-09-18
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00030264 2018-08-08
Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas
Children's Hospital of Philadelphia
Phase 2 Completed
NCT00076102 2018-04-23
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00021541 2018-04-17
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00853580 2018-03-12
STARS
University of Alabama at Birmingham
Phase 2 Completed
NCT00634270 2017-11-17
Protocol 102
University of Alabama at Birmingham
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed